Follow the trend!
PALISADE Phase 3 Clinical Program for PH94B:
The PALISADE Phase 3 clinical program has been initiated to evaluate the efficacy and safety of PH94B for the acute treatment of anxiety in adults with Social Anxiety Disorder (SAD). PH94B is an odorless, rapid-onset, investigational pherine nasal spray with a unique mechanism of action, working differently than all existing therapies for SAD. There is currently no U.S. Food and Drug Administration (FDA) approved acute treatment of anxiety for adults with SAD.
PALISADE-1 is the first clinical trial in the program and is being conducted across approximately 18 sites in the U.S., with a target of approximately 200 randomized subjects. Dr. Michael Liebowitz, a Columbia University psychiatrist, former director and founder of the Anxiety Disorders Clinic at the New York State Psychiatric Institute, director of the Medical Research Network in New York City, and creator of the Liebowitz Social Anxiety Scale (LSAS), is serving as Principal Investigator of the trial. Topline results from PALISADE-1 are anticipated in mid-2022.
I'm looking forward to VTGN speaking at Canaccord's conference next week.
5 Wall Street analysts have issued ratings and price targets for VistaGen Therapeutics in the last 12 months. Their average twelve-month price target is $6.50, predicting that the stock has a possible upside of 132.97%. The high price target for VTGN is $9.00 and the low price target for VTGN is $5.00. There are currently 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
PALISADE Phase 3 Clinical Program for PH94B:
The PALISADE Phase 3 clinical program has been initiated to evaluate the efficacy and safety of PH94B for the acute treatment of anxiety in adults with Social Anxiety Disorder (SAD). PH94B is an odorless, rapid-onset, investigational pherine nasal spray with a unique mechanism of action, working differently than all existing therapies for SAD. There is currently no U.S. Food and Drug Administration (FDA) approved acute treatment of anxiety for adults with SAD.
PALISADE-1 is the first clinical trial in the program and is being conducted across approximately 18 sites in the U.S., with a target of approximately 200 randomized subjects. Dr. Michael Liebowitz, a Columbia University psychiatrist, former director and founder of the Anxiety Disorders Clinic at the New York State Psychiatric Institute, director of the Medical Research Network in New York City, and creator of the Liebowitz Social Anxiety Scale (LSAS), is serving as Principal Investigator of the trial. Topline results from PALISADE-1 are anticipated in mid-2022.
I'm looking forward to VTGN speaking at Canaccord's conference next week.
5 Wall Street analysts have issued ratings and price targets for VistaGen Therapeutics in the last 12 months. Their average twelve-month price target is $6.50, predicting that the stock has a possible upside of 132.97%. The high price target for VTGN is $9.00 and the low price target for VTGN is $5.00. There are currently 5 buy ratings for the stock, resulting in a consensus rating of "Buy."